Status : Published Published On : Dec, 2023 Report Code : VRHC1246 Industry : Healthcare Available Format : Page : 210

Global Sepsis Treatment Market – Analysis and Forecast (2025-2030)

Industry Insights by Technology (Blood Culture, Immunoassays, Molecular Diagnostics (PCR, Peptide Nucleic Acid-Fluorescent In Situ Hybridization, Microarrays, Syndromic Panel-Based Testing), Flow Cytometry, Microfluidics, Biomarkers), by Product (Blood Culture Media, Assays & Reagents, Instruments, Software), by Pathogen (Bacterial Sepsis (Gram-Negative Bacterial Sepsis, Gram-Positive Bacterial Sepsis), Fungal Sepsis, Other Pathogen), by Test Type (Laboratory Tests, Point-of-Care Tests), by End-User (Hospitals, Pathology & Reference Laboratories, Research Laboratories & Academic Institutes)

Industry Overview

The Global Sepsis Treatment Market is expected to grow from USD 0.46 billion in 2023 to USD 0.86 billion in 2030 at a CAGR of 8.8% during the forecast period ranging from 2025 to 2030.

Sepsis is a life-threatening disease. It is caused when a specific chemical develops in the immune system and spreads into the bloodstream. The treatment includes a wide range of medical procedures and technological solutions. These help in the diagnosis of sepsis, its management and treatment. Solutions include medications and supportive care measures after proper diagnostics using different medical equipment. 

Sepsis Treatment Market Highlights

A high prevalence of this disease increases the demand for effective diagnostic solutions, which is expected to drive market growth. The rising aging population who are vulnerable to this disease due to their weaker immune system also fuels the growth of the sepsis treatment industry. Furthermore, the mandate for antibiotic-resistant bacterial strains, growing incidents of hospital-acquired infections, and the high prevalence of a wide range of chronic diseases such as diabetes may also contribute to the growth of the sepsis treatment market.

The growth of the market is somewhat hindered due to low healthcare spending among the low-income and middle-income groups. Also, the advent of a generic industry and a significant lack of public interest slows down the market growth significantly. However, laboratory and blood transfusion centers are using more innovative and effective culture-based procedures. This helps physicians to detect infected platelets donated and reduce the risk of sepsis. This creates new growth opportunities.

Market Segmentation

Insight by Technology

The Global Sepsis Treatment Market is divided by technology into blood culture, immunoassays, flow cytometry, microfluidics, biomarkers, and molecular diagnostics segments. The molecular diagnostics segment is further divided into PCR, peptide nucleic acid-fluorescent in situ hybridization, microarrays, and syndromic panel-based testing subsegments. Out of all these major segments, the blood culture segment will account for the larger share due to higher adoption and low-cost microbiology procedures.

Insight by Product

The Global Sepsis Treatment Market is divided by product into Blood Culture Media, Assays & Reagents, Instruments, and Software segments. Among all of them, the software segment is expected to grow at a higher CAGR due to the rise in the adoption of advanced technological systems by healthcare providers for better sepsis diagnosis and treatment.

Insight by Pathogen

The Global Sepsis Treatment Market is divided by pathogen into fungal sepsis, bacterial sepsis, and other segments, where the bacterial sepsis segment is further divided into gram-negative bacterial sepsis and gram-positive bacterial sepsis subsegments. Among these segments, the gram-negative bacteria segment is expected to dominate during the projected period due to the high prevalence and patient affliction. It is also attributed to the rise in R&D initiatives and growing regulatory acceptance of innovative solutions.

Insight by Test Type

The Global Sepsis Treatment Market is divided by test type into laboratory tests and point-of-care test segments. Out of these segments, the laboratory testing segment is expected to have the largest market share due to higher accuracy than POC testing, comprehensive examination of the pathogen, and higher drug resistance profile.

Insight by End User

The Global Sepsis Treatment Market is divided by end users into hospitals, pathology & reference laboratories, research laboratories & academic institutes, out of which the hospital end-user segment will account for the largest share of the sepsis treatment market. It is mainly attributed to the high prevalence of sepsis, the large number of fatalities caused, and a large number of blood culture tests performed in the in-house hospital laboratories to identify BSIs.

Global Sepsis Treatment Market Report Coverage

Report Metric


Historical Period

2018 - 2023

Base Year Considered


Forecast Period

2025 - 2030

Market Size in 2023

U.S.D.  0.46 Billion

Revenue Forecast in 2030

U.S.D.  0.86 Billion

Growth Rate


Segments Covered in the Report

By Technology, By Product, By Pathogen, By Test Type and By End-User

Report Scope

Market Trends, Drivers, and Restraints; Revenue Estimation and Forecast; Segmentation Analysis; Impact of COVID-19; Companies’ Strategic Developments; Market Share Analysis of Key Players; Company Profiling

Regions Covered in the Report

North America, Europe, Asia-Pacific, Middle East, South America and Rest of the World

Industry Trends

The most notable trends within the industry are the growing regulatory acceptance and the launch of technically innovative diagnostic solutions. In addition, the early recognition and management of sepsis have grown in importance. This is mainly because prompt intervention is vital for sepsis treatment to improve patient outcomes. This is usually done by administering antibiotics to alleviate infection and providing supportive care to improve the condition of the patient.

Growth Drivers

The most significant growth driver of the sepsis market is the growing awareness among people about early diagnosis and treatment. In addition, the technological advancements in the medical sector and the presence of a large number of pharmaceutical companies are propelling market growth. There are also a significant number of emerging players stepping into the market with their innovative treatment approaches, raising competition and growth prospects. Continual research and development initiatives to develop novel therapies for targeted treatments, such as immunomodulatory therapies, anti-inflammatory agents, and adjunctive therapies and precision medicine, are driving the sepsis market. Also, Point-of-care testing (POCT) technology and quick diagnostic tools that reduce waiting times, growing attention to innovative medicines with higher efficiency and lower side effects, and the adoption of personalized precision medicine for a more individualized approach to treatment are fueling the market growth.


One of the most significant growth hindrances is the unfavorable insurance plans. In addition, the high cost involved in such care, along with a lot of product withdrawals due to inferior efficacy, also restricts the development of the sepsis market.


A large number of groundbreaking tests for early detection and cost-effective solutions are creating new growth opportunities for the market players. These procedures typically analyze the patient's blood with a microelectrode that produces accurate results in quick time. Also, other technical developments in the existing processes to create newer and better solutions offer significant growth opportunities.

Geographic Overview

North America will account for the largest share of the global sepsis market due to a well-established medical device industry and healthcare infrastructure. It is also attributed to the widespread adoption of advanced sepsis diagnostic technology by several medical practitioners and the growth in the number of sepsis incidences in the region. Technical developments in the field also contribute to the high demand and growth of the market.

The Asia-Pacific market is expected to grow during the forecast period as well due to the growing geriatric population and the increasing prevalence of cancer and diabetes cases in countries like India, China, and Australia. In addition, the developing healthcare infrastructure in this region also propels market growth.

Market Players

•    Abbott
•    Pfizer Inc
•    GlaxoSmithKline plc
•    Bristol-Myers Squibb Company
•    Adrenomed AG
•    AM-Pharma B.V.
•    Johnson & Johnson
•    Amomed Pharma GmbH
•    Asahi Kasei Corporation
•    Endacea, Inc
•    Novartis
•    TEVA
•    InflaRx N.V.
•    Bayer
•    Shanghai Pharmaceuticals
•    La Jolla Pharmaceutical Company
•    TaiRx, Inc. 

GSK plc is a British multinational pharmaceutical and biotechnology company with global headquarters in London. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm.

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Green Oaks, Illinois, United States. 

Recent Developments by Key Players

Inotrem (an advanced clinical stage biotech company specializing in immunotherapies for acute and chronic inflammatory syndromes) has announced the outcome of its regulatory interactions with the US Food and Drug Administration (FDA) to finalize the design of a single Phase 3 registration trial (ACCURATE) for nangibotide in septic shock. 

The Sepsis Treatment Market report offers a comprehensive market segmentation analysis along with an estimation for the forecast period 2025–2030.

Segments Covered in the Report

  • By Technology
    • Blood Culture
    • Immunoassays
    • Molecular Diagnostics
    • Flow Cytometry
    • Microfluidics
    • Biomarkers
  • By Product 
    • Blood Culture Media
    • Assays & Reagents
    • Instruments
    • Software
  • By Pathogen
    • Bacterial Sepsis
    • Fungal Sepsis
    • Other Pathogen
  • By Test Type
    • Laboratory Tests
    • Point-of-Care Tests
  • By End-User
    • Hospitals
    • Pathology & Reference Laboratories
    • Research Laboratories & Academic Institutes

Region Covered in the Report

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia-Pacific (APAC)
    • China
    • Japan
    • India
    • South Korea
    • Rest of Asia-Pacific
  • Rest of the World (RoW)
    • Brazil
    • Saudi Arabia
    • South Africa
    • U.A.E.
    • Other Countries

Sepsis Treatment Market Size

Source: VynZ Research

Sepsis Treatment Market Analysis

Source: VynZ Research

Frequently Asked Questions

The global Sepsis Treatment Market is forecast to grow at an annual rate of 8.8 percent during 2025-2030.
North America accounted for the largest share of the global sepsis diagnostics market.
One of the major reasons expected to fuel demand for its diagnostics solutions is the outbreak of novel coronavirus (COVID-19) and the resulting rise in the risk of contracting sepsis.
Unfavourable insurance plans and the high cost of care are some of the factors that will limit the development of the sepsis industry.
Some key players operating in the global sepsis market include Abbott, Pfizer Inc, GlaxoSmithKline plc, Bristol-Myers Squibb Company, Adrenomed AG, AM-Pharma B.V., Johnson & Johnson, Amomed Pharma GmbH, Asahi Kasei Corporation, Endacea, Inc, Novartis, TEVA, INOTREM, InflaRx N.V., Bayer, Shanghai Pharmaceuticals, La Jolla Pharmaceutical Company, and TaiRx, Inc.

Place an order

Research Methodology

  •  Desk Research / Pilot Interviews
  •  Build Market Size Model
  •  Research and Analysis
  •  Final Deliverabvle


Key Takeaways